The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

BACKGROUND: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimumab-induced AEs have lead to a reductio...

詳細記述

保存先:
書誌詳細
主要な著者: Voskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Rüdiger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens, Vaubel, Julia, von Moos, Roger, Weder, Patrik, Wilhelm, Tabea, Göppner, Daniela, Dummer, Reinhard, Heinzerling, Lucie M.
フォーマット: Artigo
言語:Inglês
出版事項: Public Library of Science 2013
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3544906/
https://ncbi.nlm.nih.gov/pubmed/23341990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0053745
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料